PDCD1 and neoplasm: Furthermore, in estrogen receptor–positive BC, although there does not appear to be synergy between Eri and pembrolizumab (an anti–PD-1 agent), the existence of an inflamed tumor signature is associated with a clinical benefit of Eri monotherapy, suggesting a possible interaction between this molecule and the antitumor immune response (10).